Lung Cancer — Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
Citation(s)
Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features